Prevention of arthropathy in haemophilia: Prophylaxis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

At present, when resources allow, the main issue in preventing arthropathy in patients with haemophilia is determining the 'optimal' prophylaxis regimen rather than the choice between primary prophylaxis and on-demand treatment. Barriers to prophylaxis implementation are still relevant and include difficulties with venous access, adherence to treatment regimens and costs. Prospective studies with different prophylactic regimens and objective outcome measures are still needed to determine the best cost-benefit ratio. The results from large retrospective cohorts followed up for decades in several European countries have shown that regular prophylaxis started at an early age is able to reduce physical impairment from haemophilic arthropathy. The efficacy of primary prophylaxis was finally demonstrated also in the setting of a randomized clinical trial.

Original languageEnglish
Pages (from-to)16-19
Number of pages4
JournalHaemophilia
Volume14
Issue numberSUPPL. 6
DOIs
Publication statusPublished - 2008

Fingerprint

Joint Diseases
Hemophilia A
Health Care Costs
Cost-Benefit Analysis
Randomized Controlled Trials
Outcome Assessment (Health Care)
Prospective Studies
Therapeutics

Keywords

  • Haemophilia
  • Prophylaxis

ASJC Scopus subject areas

  • Genetics(clinical)
  • Hematology

Cite this

Prevention of arthropathy in haemophilia : Prophylaxis. / Santagostino, E.; Mancuso, M. E.

In: Haemophilia, Vol. 14, No. SUPPL. 6, 2008, p. 16-19.

Research output: Contribution to journalArticle

@article{0933ea9e97b1447db4be7530de9711c8,
title = "Prevention of arthropathy in haemophilia: Prophylaxis",
abstract = "At present, when resources allow, the main issue in preventing arthropathy in patients with haemophilia is determining the 'optimal' prophylaxis regimen rather than the choice between primary prophylaxis and on-demand treatment. Barriers to prophylaxis implementation are still relevant and include difficulties with venous access, adherence to treatment regimens and costs. Prospective studies with different prophylactic regimens and objective outcome measures are still needed to determine the best cost-benefit ratio. The results from large retrospective cohorts followed up for decades in several European countries have shown that regular prophylaxis started at an early age is able to reduce physical impairment from haemophilic arthropathy. The efficacy of primary prophylaxis was finally demonstrated also in the setting of a randomized clinical trial.",
keywords = "Haemophilia, Prophylaxis",
author = "E. Santagostino and Mancuso, {M. E.}",
year = "2008",
doi = "10.1111/j.1365-2516.2008.01884.x",
language = "English",
volume = "14",
pages = "16--19",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Prevention of arthropathy in haemophilia

T2 - Prophylaxis

AU - Santagostino, E.

AU - Mancuso, M. E.

PY - 2008

Y1 - 2008

N2 - At present, when resources allow, the main issue in preventing arthropathy in patients with haemophilia is determining the 'optimal' prophylaxis regimen rather than the choice between primary prophylaxis and on-demand treatment. Barriers to prophylaxis implementation are still relevant and include difficulties with venous access, adherence to treatment regimens and costs. Prospective studies with different prophylactic regimens and objective outcome measures are still needed to determine the best cost-benefit ratio. The results from large retrospective cohorts followed up for decades in several European countries have shown that regular prophylaxis started at an early age is able to reduce physical impairment from haemophilic arthropathy. The efficacy of primary prophylaxis was finally demonstrated also in the setting of a randomized clinical trial.

AB - At present, when resources allow, the main issue in preventing arthropathy in patients with haemophilia is determining the 'optimal' prophylaxis regimen rather than the choice between primary prophylaxis and on-demand treatment. Barriers to prophylaxis implementation are still relevant and include difficulties with venous access, adherence to treatment regimens and costs. Prospective studies with different prophylactic regimens and objective outcome measures are still needed to determine the best cost-benefit ratio. The results from large retrospective cohorts followed up for decades in several European countries have shown that regular prophylaxis started at an early age is able to reduce physical impairment from haemophilic arthropathy. The efficacy of primary prophylaxis was finally demonstrated also in the setting of a randomized clinical trial.

KW - Haemophilia

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=53249107710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249107710&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2516.2008.01884.x

DO - 10.1111/j.1365-2516.2008.01884.x

M3 - Article

C2 - 19134028

AN - SCOPUS:53249107710

VL - 14

SP - 16

EP - 19

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - SUPPL. 6

ER -